<br>"Preliminary analysis shows that these patients are relieved of their symptoms within 24 hours of the monoclonal therapy and their RT-PCR reports also showed viral clearance within a week," Asian Institute of Gastroenterology (AIG) Chairman, Dr D. Nageshwar Reddy, told IANS on Tuesday.This is the first of its kind study in India where experts are looking for the efficacy of this monoclonal antibodies cocktail, especially with the Delta variant (B.1.617), of the virus. "Our plan is to include at least 100 patients for this study. Already 50 patients have been given the drug and we are following up these patients," he said.The patients were given the single dose monoclonal antibodies cocktail drug (casirivimab and imdevimab) within 5 days of their first symptom onset. These patients are in various age groups but majorly 65 plus with comorbidities like diabetes, hypertension, and obesity. Those who were in younger age group were in high-risk category including being on immunosuppressants. According to Dr Reddy, the results till now have been consistent among all these patients."Studies which were conducted in the US showed that this drug cocktail is effective against the Alpha, Beta and Gamma variants of the virus. The primary objective of the study that we are conducting is to see the efficacy of this monoclonal therapy on the Delta variant (B.1.617) that is now the most prevent strain," he said.The combination of drugs that is being currently used in this antibody cocktail is made by Roche and marketed by Cipla in India. This contains two monoclonal antibodies, Casirivimab and Imdevimab.In India, Zydus recently got the approval to conduct clinical trials by the Subject Expert Committee of the Central Drugs Standard Control Organisation for their antibody cocktail. Currently, the cost of the Roche antibody cocktail comes around Rs 60,000.Patients over 65, obese patients, with uncontrolled diabetes, cardiovascular patients, chronic kidney disease patients and those who are under immunosuppressants like cancer patients are ideal candidates for this treatment."The timing also must be appropriate where it needs to be given within three to seven days at max. This can be given to patients above 55 if they have heart related issues like hypertension," Dr Reddy said."Pregnant women and children below 12 years of age are not supposed to be given this treatment as we don't have enough safety data for this subset of patients," he added.Dr Reddy had earlier cautioned against irrational use of antibody cocktails. "This treatment has the potential to increase mutant variants and that is why irrational use of these antibodies' cocktails should be absolutely discouraged," he said.Clinical studies published in peer-reviewed journals including the New England Journal of Medicine have shown that antibody cocktails reduce hospitalisation or death by over 70 per cent, including a drastic reduction in viral clearance.Roche's antibody cocktail was given to then US President Donald Trump when he contracted Covid-19 last year.The doctors say that the cocktail is to be given only in a hospital setting where there is provision to activate the emergency medical system immediately following any infusion-related adverse reaction.(Mohammed Shafeeq can be contacted at [email protected])--IANS<br>ms/vd
London, June 15 (IANS) British-Swedish biopharmaceutical company AstraZeneca on Tuesday stated that its monoclonal antibody treatment failed to prevent the Covid-19 symptoms in individuals already exposed to the virus.The Covid-19 antibody therapy -- AZD7442 -- was only 33 per cent effective in reducing the risk of symptoms, when compared to a placebo, according to the results of a Phase 3 trial."While this trial did not meet the primary endpoint against symptomatic illness, we are encouraged by the protection seen in the PCR negative participants following treatment with AZD7442," Executive Vice President, BioPharmaceuticals R&D, Mene Pangalos, said in a statement.The Phase 3 trial included 1,121 participants, from the UK and the US. The participants were unvaccinated adults 18 years and above with confirmed exposure to a person with a case of the SARS-CoV-2 virus within the past eight days.All participants had a negative SARS-CoV-2 antibody test on the day of dosing to exclude prior infection, and a nasopharyngeal swab was also collected and subsequently analysed for SARS-CoV-2 by RT-PCR to detect virus. The results are not peer reviewed yet."The results of the study suggest that AZD7442 may be useful in preventing symptomatic Covid-19 in individuals not already infected," said principal investigator on the trial Myron J Levin, Professor at University of Colorado School of Medicine, US.AZD7442 is a combination of two LAABs - tixagevimab (AZD8895) and cilgavimab (AZD1061) - derived from B cells donated by convalescent patients after SARS-CoV-2 virus. Discovered by Vanderbilt University Medical Center and licensed to AstraZeneca in June 2020, the human monoclonal antibodies bind to distinct sites on the SARS-CoV-2 spike protein2 and were optimised by AstraZeneca with half-life extension and reduced Fc receptor binding.The therapy is currently being tested in several additional Covid prevention and treatment trials: Phase 3 trial of over 5,000 participants in pre-exposure prophylaxis; Phase 3 treatment trial in outpatient setting; and collaborator treatment trials in outpatient and hospitalised settings.--IANSrvt/vd
Hyderabad, June 15 (IANS) Apollo Hospitals Group Joint Managing Director, Dr Sangita Reddy has said that she received Regeneron's monoclonal antibody cocktail and this made a "dramatic difference".She revealed that she tested positive for Covid-19 on June 10 and was hospitalised with high fever. Sangita Reddy said she took the antibody therapy within the early window period."After 500 days of dodging Covid-19, I tested +VE on June10th My initial reaction was of shock & dismay - Why me? I was careful & vaccinated Hospitalized with high fever I took the cocktail Regeneron therapy within the early window period & it has made a dramatic difference," she tweeted.Sangita Reddy, who is also a former President of the Federation of Indian Chambers of Commerce & Industry (FICCI), wrote on the micro blogging platform that while vaccines don't prevent Covid, they help keep symptoms mild.According to her, timely diagnosis and treatment are key to quick recovery. On her discharge from hospital, she conveyed her heartfelt gratitude to nurses, doctors and entire scientific community.She said that she will remain under self-isolation under medical supervision through telemedicine."Feeling fine. Thank you all for your good wishes. Prayers. Jokes. Words of encouragement. Truly appreciate it The human race is indeed a single tribe. Our bonding makes us stronger take care n stay well," Sangita Reddy tweeted again responding to messages by her well wishers.--IANSms/vd
New York, June 10 (IANS) A day after Delhi-based Sir Gangaram Hospital claimed that monoclonal antibody can be a game changer with its better hold on the deadly Covid pandemic, a study led by Mayo Clinic said that treating transplant patients infected with mild to moderate Covid-19 with monoclonal antibodies is safe and helps prevent serious illness.The study is important because transplant patients who are infected with Covid-19 have a higher risk of severe illness and death."Monoclonal antibody therapy is really important for the transplant population because they are less likely to develop their own immunity. Providing them with these antibodies helps them recover from Covid-19," said Raymund Razonable, Mayo Clinic infectious diseases specialist.The study, published in the journal Open Forum Infectious Diseases, focused on the first 73 solid organ transplant patients who received monoclonal antibody infusions for treatment of mild to moderate Covid-19 between November 19, 2020, and January 23 at Mayo Clinic.Eleven patients had an emergency department visit and nine patients were hospitalized. Most significantly, no patients required mechanical ventilation, died or experienced organ rejection."While we expected monoclonal antibody therapy would be beneficial for patients, we were pleasantly surprised by the results. Only one patient required care in the ICU for non-Covid-19 indication, and, most importantly, there were no deaths," Razonable said.Monoclonal antibodies help prevent the virus that causes Covid-19 from attaching to human cells, which helps block the spread of infection.In 2020, the US Food and Drug Administration authorised the emergency use of Monoclonal antibodies bamlanivimab and casirivimab-imdevimab to treat mild to moderate Covid-19 in patients with a high risk of becoming seriously ill.A previous study led by University of Pittsburgh researchers also found that people aged 65 and older who received bamlanivimab were nearly three times less likely to be hospitalised or die in the following month, compared to their untreated counterparts.The therapy is also available in India, and hospitals including Medanta in Gurugram, BLK-Max Super Speciality and Sir Gangaram in New Delhi, have successfully implemented the treatment.--IANSrvt/in
New Delhi, June 9 (IANS) At a time when the country is passing through the second wave of Covid-19, Delhi-based Sir Gangaram Hospital claims that monoclonal antibody can be a game changer with its better hold on the deadly pandemic.As per the hospital, the monoclonal antibodies will change the scenario of Covid-19 pandemic very soon.The healthcare facility came with new findings after treatment of two patients recently at its centre by successfully using monoclonal antibody which showed fast progression of symptoms within first seven days and changed the outcome.A 36-year-old healthcare worker with high grade fever, cough, myalgia, severe weakness and leucopenia was administered REGCov2 (CASIRIVIMAB Plus IMDEVIMAB) on day six of disease, the hospital said in a statement."Patient's parameter improved within 12 hours and was discharged," said the hospital.The second case was of R.K. Razdan, an 80-year-old male diabetic and hypertensive patient, who was presented with high grade fever, cough and toxic look.Razdan's oxygen saturation was more than 95 per cent on room air. "CT Scan confirmed mild disease. He was given REGCov2 on Day 5 of disease. Patient's parameter improved with next 12 hours."According to Pooja Khosla, Senior Consultant, Department of Medicine, Sir Ganga Ram Hospital, "Monoclonal antibody could prove to be a game changer in times to come if used at appropriate time.""It can avoid hospitalization in high-risk group and progression to severe disease. It can help escaping or reducing the usage of steroids and immunomodulation which would further reduce the risk of fatal infections like Mucormycosis, secondary bacterial and viral infections like CMV."Khosla said this awareness about early identification of high-risk category in our population and timely therapy with monoclonal antibody as day care treatment may reduce the burden of cost on healthcare sector.--IANSrak/in
Hyderabad, June 9 (IANS) Covid-19 pandemic and lockdown are affecting children with autism as fear of contracting the virus is making parents skip therapy.Experts say delaying therapy due to Covid fear and restrictions is adding to the problems of children.Parents with autistic children are refusing the therapy because they are afraid their kid might get infected through every conceivable way if they take them down to the center. According Sreeja Reddy Saripalli, founder and chief strategist, Pinnacle Blooms Network, the problem is persisting since the first phase of Covid hit the country in March last year. "Adults themselves have cut down on their interaction with outside world over the past 14 months which means, even children, who are in desperate need of help, are held back from reaching out to social workers," she said.Since much of the brain development happens when the baby is between 12 and 60 months, she said delaying therapy will add to the problems."Babies are born with 25 per cent of their brain. As baby reaches their one year mark, it increases by 50 percent. By the time the child is 48 to 60 months, which is, four to five years old, the brain is fully developed. The development of the brain, which collects signals from the five senses and delivers them to the baby, must take place before the baby is 12 to 60 months old. Otherwise the motor and executive functions that the child should be capable of doing on their own will most certainly be impaired," said Sreeja ReddyShe believes that missing crucial months (12 to 60 months) will render kid dependent and unable to navigate through life without parent's aid. It is of utmost importance that parents get them the therapy they require to build their motor and executive functions.She said since controlling Covid symptoms in the second phase has become much easier due to growing awareness about the virus and an array of instructions on how to avoid getting infected, parents must ensure that their child does not miss even a single day of therapy.As with food, children with autism tend to be picky with their environment. Choosing to be in their room instead of socializing with others, they get little to no interaction. To compensate for that, parents usually bring their kids to park so they can observe and have contact with the world outside on their terms so they're not totally cut off from it. This form of interaction too has been disrupted by Covid. "It's a total myth that autistic kids of all kids are at high risk of catching the virus because of their immunity. Take them out, let them still meet people, make them wear masks, double it up if necessary, make them wear gloves, but bring them to the park and let them enjoy watching cats and people go by," she said.Pinnacle Blooms has floated a free national helpline 9100181181 to help parents.According to Charan Teja Koganti, Consultant Neuropsychiatrist, KIMS Hospitals, Hyderabad, with pandemic there is an increase in the behavioural symptoms of autistic kids that include irritability, worry, tantrums and fear."Attending speech therapy, occupational therapy and child guidance clinics might be delayed due to disrupted medical services and lockdown which can interfere with the ongoing treatment for autism," said the doctor.He also believes that financial burden of parents can halt foregoing therapies entirely due to cost, which can lead to worse long-term behavioral outcomes. There may be a failure to develop skills especially social and communication which they lack due to limited or no contact with other children with suspension of in-person education, extracurriculars and social activities. Picky eating and oral aversion can be a challenge due to unavailability of their favorite food at a restaurant or in the grocery store, Charan Teja added.--IANSms/in
Dear Patron, Please provide additional information to validate your profile and continue to participate in engagement activities and purchase medicine.